High-protein diet based on whey protein isolate preserves muscle mass and its association with resistance training attenuates glomerular hypertrophy in rats.

Objective: To evaluate the effect of administering a high-protein diet (HP) based on whey protein isolate (WPI) associated with ST in rats.

Methods: Twenty-two Wistar rats were fed a diet containing either 14% WPI (normoproteic) or 35% WPI (high protein) and were subjected to stair training or kept sedentary for 12 weeks. SN = sedentary normoproteic; SH = sedentary high protein; TN = trained normoproteic; TH = trained high protein.

Adoptive T Cell Therapy Targeting MAGE-A4.

MAGE A4 (Melanoma Antigen Gene A4) is a cancer testis antigen (CTA) that is expressed normally in germline cells (testis/embryonic tissues) but absent in somatic cells. The MAGE A4 CTA is expressed in a variety of tumor types, like synovial sarcoma, ovarian cancer and non-small cell lung cancer. Having its expression profile limited to germline cells has made MAGE A4 a sought-after immunotherapeutic target in certain malignancies.

Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: A systematic review and updated meta-analysis.

Background: Trastuzumab deruxtecan (T-DXd) has shown promising activity in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) and central nervous system (CNS) involvement. In this updated meta-analysis, we explore the effectiveness of T-DXd in a large subset of patients with HER2-positive BC and CNS disease.

Methods: A systematic search was made on September 16th, 2024, for studies investigating T-DXd in the scenario of HER2-positive BC and brain metastases (BMs) and/or leptomeningeal disease (LMD).

Prevalence of gene mutation and its expression in Brazilian pediatric B-ALL patients: clinical implications.

Introduction: There is consistent evidence that may be a driver gene in B-ALL and that selected cases may benefit from the use of FLT3 inhibitors. Our study was conducted to evaluate the frequency and types of FLT3 mutations in pediatric patients with B-ALL, the relative expression of this gene, and their influence on clinical evolution.

Methods: We evaluated 156 children with B-ALL treated between July 2018 and September 2023.